The finite dose technique as a valid in vitro model for the study of percutaneous absorption in man.
An in vitro model of percutaneous absorption has been developed which permits close stimulation of conditions commonly associated with topical drug use in living man. Quantitative comparison of the absorption of selected compounds in the model and in living man was made to test the validity of the model. Excellent agreement has been found between the two sets of data, both with respect to the total amount absorbed and the kinetics of absorption.
D001241:Aspirin / Q000378:metabolism; D001565:Benzoates / Q000378:metabolism; D002110:Caffeine / Q000378:metabolism; D002701:Chloramphenicol / Q000378:metabolism; D004137:Dinitrochlorobenzene / Q000378:metabolism; D006626:Hippurates / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D008954:Models, Biological; D009539:Nicotinic Acids / Q000378:metabolism; D010636:Phenols / Q000378:metabolism; D012459:Salicylates / Q000378:metabolism; D012869:Skin Absorption; D014508:Urea / Q000378:metabolism
D001565:Benzoates; D004137:Dinitrochlorobenzene; D006626:Hippurates; D009539:Nicotinic Acids; D010636:Phenols; D012459:Salicylates; D002110:Caffeine; D002701:Chloramphenicol; D014508:Urea; D001241:Aspirin